ALISO VIEJO, Calif. - Glaukos Corporation (NYSE:GKOS), a pioneer in ophthalmic medical technology, has released its preliminary and unaudited net sales figures for the fourth quarter and the full year of 2023. The company, known for its innovative treatments for eye diseases, reported that its net sales for the last quarter are expected to be in excess of $81M, and total sales for the year surpassed $313M.
Looking ahead, Glaukos has reaffirmed its sales guidance for 2024, projecting revenues to be between $350M and $360M. This forecast aligns with the company's ongoing efforts to expand its portfolio and maintain its commitment to advancing eye care through novel medical devices and pharmaceutical solutions.
Since launching its first Micro-Invasive Glaucoma Surgery (MIGS) device in 2012, Glaukos has continued to lead in developing alternative treatments to traditional eye care methods. The company's focus spans across various eye conditions, including glaucoma, corneal disorders, and retinal diseases, aiming to improve the standard of care with better treatment options.
The forward-looking statements provided by Glaukos are based on expectations of future events and are subject to risks and uncertainties. These include regulatory approvals, successful commercialization, competition within the pharmaceutical industry, and the efficacy and safety of their products. The company has detailed these risks in its recent SEC filings, which are publicly available for review.
The information provided in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.